Empagliflozin

Empagliflozin

sodium-glucose cotransporter 2 (SGLT-2)

Renal Glucose re absorption via SGLT2

The U.S. Food and Drug Administration on 1st August 2014 approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes.

It is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys

SGLT-2 inhibitors such as empagliflozin reduce blood glucose by blocking glucose reabsorption in the kidney and thereby excreting glucose (i.e., blood sugar) via the urine.

Empagliflozin is a sodium glucose cotransporter 2

(SGLT2) inhibitor that blocks the reabsorption of

glucose by the kidney, increases glucose excretion,

and lowers blood glucose levels. It has been studied

"as a stand-alone therapy and in combination with

other type 2 diabetes therapies including metformin,

sulfonylureas, pioglitazone, and insulin," according

to FDA statement announcing the approval.

This is the third SGLT2 inhibitor approved by the FDA, following the approval of

dapagliflozin (Farxiga)in January 2014

And

canagliflozin (Invokana)

in March 2013.

The sodium glucose cotransporter 2 (SGLT2) is indicated for improving glycemic control in adults with type 2 diabetes in conjunction with diet and exercise

THANK YOU

kammph@gmail.com

REFERENCES :-

http://www.clinicalendocrinologynews.com/home/article/fda-approves-empagliflozin-for-adults-with-type-2-diabetes/e8e500442424cf39148f889d6fe6b16c.html

http://www.medscape.com/viewarticle/829326

http://www.nature.com/nrd/journal/v9/n7/full/nrd3180.html

http://www.google.co.in/imgres?imgurl=http%3A%2F%2Fimg.medscape.com%2Ffullsize%2Fmigrated%2Feditorial%2Fconferences%2F2008%2F15780%2Fwilding.fig1.gif&imgrefurl=http%3A%2F%2Fwww.medscape.org%2Fviewarticle%2F578176&h=435&w=547&tbnid=DoFxRsCDfjXAcM%3A&zoom=1&docid=JABzUQ1hypWRpM&ei=7v7hU_niA4WOuAS7sgE&tbm=isch&client=firefox-a&ved=0CB8QMygDMAM&iact=rc&uact=3&dur=763&page=1&start=0&ndsp=15